The Resveratrol study is a Phase 2, multicenter, placebo-controlled study in mild to moderate AD patients sponsored by the National Institute on Aging through the Alzheimer's Disease Cooperative Study. This study's primary objective is to assess the safety and tolerability of the treatment of resveratrol over a 12-month period as assessed by laboratory tests, cognitive and functional testing, biomarkers, and MRI results. Another objective of the study is to determine whether resveratrol affects insulin and glucose metabolism.

This is a medical research study designed to look at how well an oral dose of CB 183,315 and oral vancomycin work against CDAD (Clostridium difficile Associated Diarrhea) as well as the safety of these medicines. CDAD is a condition caused by the inflammation of the toxin produced by a type of bacteria called C. difficile. The infection can happen when the normal flora of the colon is changed after a patient is treated with antibiotics. The decrease in this normal flora allows for the growth of the C. difficile bacteria.

The purpose of this study is to compare the effects of hormone therapy (androgen deprivation) and radiation therapy to the prostate gland and seminal vesicles with hormone therapy and radiation therapy to the whole pelvic body area on prostate cancer to find out which is better.

There are 2 treatment groups in this study:
1) Patients who receive hormone therapy plus radiation therapy to the prostate gland and seminal vesicles (two small glands behind the prostate)
2) Patients who receive hormone therapy plus radiation therapy to the whole pelvis

The purpose of this study is to find out what effects (good and bad) a targeted therapy (specific treatment that is based on certain genes found in tumor cells) approach has on subjects and their esophageal, gastric, or gastroesophageal junction cancer.

This research is being done because currently there is no advanced knowledge of which patients will benefit from which type of chemotherapy.

Colorectal adenomas are tiny growths in the colon that may eventually lead to cancer. The purpose of this study is to determine if eflornithine and sulindac, taken alone or in combination, can decrease the risk of high-risk adenomas or second primary colorectal cancers in patients who have been treated for Stage 0, I, II, or III colon cancer. ("Second primary colorectal cancer" means a new colorectal cancer developing within the colorectum.)

The study drugs eflornithine and sulindac are tablets which are taken orally (by mouth). Sulindac is FDA approved and is commercially available but is not approved for this indication. Eflornithine cream is FDA approved, but oral eflornithine is an investigational agent and not approved by the FDA.

This study is being done for the following reasons:
•This study is being done to find out if a combination of just two chemotherapy drugs, docetaxel and cyclophosphamide, is as good as using different combinations of the chemotherapy drugs doxorubicin and cyclophosphamide, given with either docetaxel or paclitaxel, in treating your type of breast cancer. All of these drugs are used in standard combinations of chemotherapy for breast cancer.
•The researchers also want to learn about the side effects of the combinations of drugs used in this study. Side effect information will also be studied to see if there are any differences between the two-drug and three-drug chemotherapy combinations.
•In order to learn more about cancer tumors, this study includes special research tests that will be done on tumor tissue that was removed during your breast cancer surgery. Information about this study requirement will be explained to you in more detail later in this consent form.

This randomized phase III trial is studying the use of hormone therapy, including TAK-700, together with radiation therapy in treating patients with prostate cancer.

The purpose of the study is to assess the safety and efficacy of N-Acetylcysteine (NAC) in preventing relapse to cocaine use. In order to participate in this research study you must be currently enrolled in an intensive outpatient treatment program and addicted to cocaine. This study is being conducted at the Medical University of South Carolina Institute of Psychiatry, Center for Drug and Alcohol Programs (CDAP).

Oxytocin has been shown to promote trust, social bonding, and calmness; however, its potential additive effects with a therapy intervention have not been explored in marijuana-dependent individuals. In the proposed study, the impact of intransal oxytocin on therapy effectiveness, drug craving, and marijuana use outcomes following a brief therapy intervention will be investigated.

Our recently completed study has provided the first evidence that administration of the medication propranolol, following exposure to cocaine cues, can alter drug-associated memories and reduce craving and other drug cue-elicited responses in cocaine addicted persons. The proposed research will use two methods to increase the memory altering effects of propranolol observed in our recently completed study, and document lasting effects not only on craving and cue-elicited reactions, but also on cocaine use. Positive findings will set the stage for a formal clinical trial that could lead to significantly improved treatment outcomes for this treatment-resistant addiction.